Stockreport

Repare Therapeutics' individualised anaemia management trial shows promise [Yahoo! Finance]

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF The trial involved treating subjects with a combination of a first-in-class protein kinase, membrane-associated tyrosine/threonine one (PKMYT1) inhibitor, lunresertib, [Read more]